132 results on '"Minařík, Jiří"'
Search Results
2. PORT: A Randomized, Cross-Over, Phase 2 Study of Melflufen Peripheral Versus Central Intravenous Administration in Patients With Relapsed/Refractory Multiple Myeloma
3. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study
4. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study
5. Patient Characteristics, Treatment Patterns, and Outcomes in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Patients, a Retrospective Observational Study Using Czech Registry Data
6. Hereditary haemorrhagic teleangiectasia (Rendu-Osler-Weber disease)
7. Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies
8. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma
9. Molecular Cytogenetic Analysis of Chromosome 8 Aberrations in Patients With Multiple Myeloma Examined in 2 Different Stages, at Diagnosis and at Progression/Relapse
10. Involvement of Small Non-Coding RNA and Cell Antigens in Pathogenesis of Extramedullary Multiple Myeloma
11. Immunomodulatory Agents for Multiple Myeloma
12. Breakthrough COVID-19 in Vaccinated Patients with Haematologic Malignancies—The First Single-Centre Experience from the Czech Republic
13. Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM): Characterization of Subsequent Antimyeloma Therapies
14. Patient Characteristics and Survival Outcomes of Lenalidomide Exposed non- Refractory vs. Lenalidomide Refractory Multiple Myeloma Patients in the HONEUR Federated Data Network
15. 10 years of experience with thalidomide in multiple myeloma patients: Report of the Czech Myeloma Group
16. Retinal oxygen saturation in monoclonal gammopathies patients: A pilot study.
17. Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine
18. Real-world evidence of efficacy and safety of pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: Czech registry data
19. Combined measurement of plasma cell proliferative and apoptotic index in multiple myeloma defines patients with good and poor prognosis
20. Treatment of multiple myeloma in 2021
21. Multicentered patient-based evidence of the role of free light chain ratio normalization in multiple myeloma disease relapse
22. Bortezomib‐based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data
23. Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma
24. Safety and Tolerability of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Safety Run-in Results from a Phase 2 Study
25. P-159 Lenalidomide maintenance in R2-ISS stratified multiple myeloma patients - real world evidence
26. P-075 Real-world evidence on prognostic value of minimal residual disease in multiple myeloma: Czech experience
27. P-063 Comparison of whole-body imaging in multiple myeloma with respect to lytic involvement and presence of extramedullary disease
28. P-042 Early infections in myeloma patients treated with anti-BCMA bispecific antibodies
29. Identification of patients with smouldering multiple myeloma at ultra‐high risk of progression using serum parameters: the Czech Myeloma Group model
30. Ohlédnutí za 2. českým hematologickým a transfuziologickým sjezdem.
31. Clinical Impact of Basophilia during Cytoreduction in Patients with Chronic Myeloid Leukaemia
32. p16INK4a in the Gut Mucosa Associates with NFKB1 Gene Polymorphisms and Decreased Serum Levels of Inflammation-Associated Proteins in Patients with Gastrointestinal Acute Graft Versus Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation
33. P-177: Outcomes in risk-stratified patients with smoldering multiple myeloma: a retrospective analysis of real-world data from the Czech Registry of Monoclonal Gammopathies
34. P-147: Renal transplant in light chain deposition disease – salvation or highway to hell? A case presentation
35. OAB-052: Isatuximab plus pomalidomide/low-dose dexamethasone versus pomalidomide/low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (ICARIA-MM): final overall survival analysis
36. Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in Czech Republic
37. PORT (OP-109): Phase 2, Randomized, Pharmacokinetic (PK), Cross-over Study of Peripheral Vs Central Intravenous Administration of Melflufen in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
38. P-205: PORT (OP-109): Phase 2, randomised, Pharmacokinetic (PK), cross-over study of peripheral vs central intravenous administration of Melflufen in patients with Relapsed/Refractory Multiple Myeloma (RRMM)
39. Selected Genetic Polymorphisms Associated with Hypoxia and Multidrug Resistance in Monoclonal Gammopathies Patients
40. Differential diagnosis of monoclonal gammopathies from the point of clinical practiceII. Monoclonal gammopathy of undetermined significance and other monoclonal gammopathies of the "non-malignant" origin
41. Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patients
42. Differential diagnosis of monoclonal gammopathies from the point of clinical practiceI. Malignant monoclonal gammopathies
43. Vliv zatížení a tlaku huštění pneumatik traktoru na utužení půdy
44. Vyhodnocení ohroženosti pozemků vodní erozí na vybraném území
45. The Role of Demographic and Social Factors on Decision Making in Patients with Relapsed and Refractory Multiple Myeloma Treated By Ixazomib, Lenalidomide and Dexamethasone
46. Next-Generation Optical Mapping Reveals Numerous Previously Unrecognizable Structural Variants in Chronic Lymphocytic Leukemia
47. Overall Survival Benefit of Ixazomib, Lenalidomide and Dexamethasone (IRD) over Lenalidomide and Dexamethasone (RD) in RRMM Patients Treated in Routine Clinical Practice: Results from the Czech Registry of Monoclonal Gammopathies (RMG)
48. Registry of Monoclonal Gammopathies (RMG) - the monitored real-world database of the Czech Myeloma Group
49. Real-world comparison of Ixazomib, lenalidomide and dexamethasone vs lenalidomide and dexamethasone in relapsed and refractory multiple myeloma
50. Comparison of Radiodiagnostic Methods (Conventional Radiography, Low-Dose Computed Tomography and Magnetic Resonance Imaging) With Selected Markers of Bone Metabolism and Bone Marrow Microenvironment
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.